Ak47 Menthol Warming
Menthol Warming
Crosstown Concepts Corporation
Human Otc Drug
NDC 90078-521Ak47 Menthol Warming also known as Menthol Warming is a human otc drug labeled by 'Crosstown Concepts Corporation'. National Drug Code (NDC) number for Ak47 Menthol Warming is 90078-521. This drug is available in dosage form of Cream. The names of the active, medicinal ingredients in Ak47 Menthol Warming drug includes Menthol - 5.6 g/112g . The currest status of Ak47 Menthol Warming drug is Active.
Drug Information:
| Drug NDC: | 90078-521 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Ak47 Menthol Warming |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Menthol Warming |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Crosstown Concepts Corporation |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Cream |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | MENTHOL - 5.6 g/112g
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | TOPICAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | OTC MONOGRAPH NOT FINAL |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 20 Jul, 2020 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 22 Dec, 2025 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | part348 |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | Crosstown Concepts Corporation
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UNII: | L7T10EIP3A
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 90078-521-01 | 1 JAR in 1 BOX (90078-521-01) / 112 g in 1 JAR (90078-521-04) | 20 Jul, 2020 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Topical analgesic
Product Elements:
Ak47 menthol warming menthol warming linalool, (+)- menthol menthol caryophyllene pinene cetostearyl alcohol c13-14 isoparaffin laureth-7 magnesium chloride cannabidiol limonene, (+)- stearic acid mangifera indica seed butter coconut oil phenoxyethanol polyacrylamide (10000 mw) witch hazel corn oil myrcene terpineol peg-100 stearate white wax cetearyl glucoside shea butter cannabis sativa seed oil olive oil peppermint oil water glyceryl monostearate tabasco pepper
Indications and Usage:
Uses: for temporary relief of minor aches and pains associated with arthritis simple backache muscle strains sprains bruises
Warnings:
For external use only
When Using:
When using this product: do not bandage tightly avoid contact with eyes do not apply to wounds or damaged skin do not use heating pads or other heating devices.
Dosage and Administration:
Directions adults and children 12 years of age and older apply generously to affected area massage into painful area until thoroughy absorbed into skin repeat as necessary.
Stop Use:
Stop use and ask a doctor if: condition worsens or if symptoms persist for more than 7 days or clear up and occur again within a few days.
Package Label Principal Display Panel:
Cooling cream label cooling cream box cooling cream label cooling cream box
Further Questions:
Questions or comments info@ak47painrelief.com